GlassScriptPhysician profile
Nalini Agarwal
NPI 1073603213
$1,399.00
in general payments reported to CMS, 2019-2025
20 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $95.43 · 2021: $17.35 · 2022: $188 · 2023: $17.49 · 2024: $346 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $277.89 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $191.71 | 2022-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.96 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $131.39 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $113.52 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $100.91 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $69.17 | 2019-2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $64.12 | 2024 | Cobenfy |
| Indivior INC. | $29.20 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $29.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.95 | 2020 | |
| Abbvie INC. | $27.89 | 2025 | |
| Sage Therapeutics, LLC | $26.83 | 2025 | Zurzuvae |
| Allergan, INC. | $24.14 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.32 | 2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.57 | 2024 | Azstarys |
| Noven Therapeutics, LLC | $17.37 | 2025 | Xelstrym |
| Lundbeck LLC | $15.73 | 2019 | |
| Tris Pharma INC | $13.38 | 2019 | |
| Shire North American Group INC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalini Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.